Form PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)					ATTY. DOCKET NO. 2132.092 APPLICATION NO. 09/993,289				
					APPLICATION NO. 2132.092  APPLICATION NO. 09/993,289  APPLICANT JACKOWSKI et al.  FILING DATE 11/23/01  CLASS SUBCLASS  FILING DATE 1 641				
					FILING DATE GROUP 11/23/01 164			41	CENTER 10
			U.S. PAT	TENT DOCUMENTS					-00
EXAMINER'S		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING IF APPR	DATE OPRIATE
						<u> </u>		<u> </u>	
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSL	ATION
12	1 1	O 01/75454	10/01	PCT		X		YES	NO_
1		O 98/22617	05/98	PCT		$\prec$	$\int$	X	
1,		O 95/25281	09/95	PCT		<del>-  </del>	$\overline{}$	×	
V		2 1 070 962	01/01	Europe		/1		X	
	•		NTS (Including	Author, Title, Date,	Pertinent	Pages, E	tc.)		
	Howard, et al., "Antibodies to fibronectin bind to plaques and other structures in Alzheimer's disease and control brain", Neuroscience Letters (1990) Vol. 118, No. 1, pp. 71-76.  Kashiwagi, et al., "Sequential Changes in Plasma Fibronectin in Patients with Subarachnoid Hemorrhage", Neurol Med Chir (1993) Vol. 33, No. 4, pp. 225-228.  Rattan, et al., "Unchanged concentration of plasma fibronectin in Alzheimer's disease", Journ of Clinical Pathology (1988) Vol. 41, No. 4, p.476.							d	
				high resolution separ ol. 771, No. 1-2, pp.			ebrospinal	fluid", Jou	urnal
		Schrader, et al. (2001) Vol. 19,		technolgies for hum 55-560.	an body f	fluids", Tro	ends in Biot	echnolog	у
		Retta, et al., "Purification of Fibronectin from Human Plasma", Methods in Molecular Biology (1999) Vol. 96, pp. 119-130.							
				novel truncated forms (2003) Vol. 537, No				orotein in	
EXAMINER	Litta	1.12		DATE CONSIDERED	10/2	163			
	-1111				, -	7 4			